Shots:

• AstraZeneca collaborates with Gatehouse Bio to explore new targets for respiratory and CV diseases utilizing Gatehouse Bio’s AI-powered sRNAlytics platform
• The collaboration allows Gatehouse Bio to develop next-generation therapies and epitomizes its focus on Bio Hub Incubator. In 2018- Gatehouse Bio joined AstraZeneca’s Boston Bio Hub Incubator to accelerate their research and developed pipeline of RNA sequencing with biology-influenced ML algorithms after 18mos.
• Gatehouse Bio’s sRNAlytics platform highlights molecular pathways of diseases via analyses of small RNA- then insights are converted to therapeutic targets and CDx

Click here to­ read full press release/ article 

Ref: PRNewswire | Image: AstraZeneca